Therapeutic compounds for HIV virus infection

A compound of Formula I,

• or a pharmaceutically acceptable salt thereof,
• wherein
• X is C3-7 monocyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, or 8-10 membered fused bicyclic heteroaryl, wherein the C3-7 monocyclic cycloalkyl, 4-7 membered monocyclic heterocyclyl, phenyl, naphthalenyl, 5-6 membered monocyclic heteroaryl, and 8-10 membered fused bicyclic heteroaryl are each independently optionally substituted with 1-3 R1 groups;
• each R1 independently is —CN, halogen, Ra, Rb, Rc, C1-6 alkyl, or 4-7 membered monocyclic heterocyclyl,
• wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, Ra, Rb, Rc, —SR2, and ═NR2a,
• wherein the 4-7 membered monocyclic heterocyclyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, Ra, Rb, and Rc;
• each Ra independently is —P(O)(OH)2 or —OP(O)(OH)2;
• each Rb independently is —C(O)R2, —C(O)OR2, —C(O)NR3R3, —C(O)C(O)OR2, —S(O)2R2, —S(O)2NR3R3, or —S(O)2OR3;
• each Rc independently is —OR2, —OC(O)R2, —OC(O)C(O)OR2, —NR3R3, —N+R3R3R3a, —NR3C(O)R2, —NR3C(O)NR3R3, —NR3C(O)OR2, —NR3C(O)C(O)OR2, or NR3S(O)2R2;
• each R2 independently is H or C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, Ra, Rd, and Re;
• each R2a independently is H or C1-3 alkyl;
• each R3 independently is H, —C(O)OR4, or C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from —CN, halogen, Ra, Rd, Re, and ═NR3a;
• each R3a independently is H or C1-3 alkyl;
• each Rd independently is —C(O)R4, —C(O)OR4, —C(O)NR4R4, —C(O)C(O)OR4, —S(O)2R4, —S(O)2NR4R4, or —S(O)2OR4;
• each Re independently is —OR4, —OC(O)R4, —OC(O)C(O)OR4, —NR4R4, —N+R4R4R4a, —NR4C(O)R4, —NR4C(O)NR4R4, —NR4C(O)OR4, —NR4C(O)C(O)OR4, or —NR4S(O)2R4;
• each R4 independently is H or C1-6 alkyl, wherein the C1-6 alkyl is optionally substituted with 1-3 groups independently selected from —OH, CN, halogen, —COOH, and Ra;
• wherein each 4 membered monocyclic heterocyclyl has 1 ring heteroatom selected from N, O, and S;
• wherein each 5-7 membered monocyclic heterocyclyl has 1-2 ring heteroatoms independently selected from N, O, and S;
• and
• wherein each 5-6 membered monocyclic heteroaryl and 8-10 membered fused bicyclic heteroaryl independently have 1-4 ring heteroatoms independently selected from N, O, and S.